Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

4PJT

Structure of PARP1 catalytic domain bound to inhibitor BMN 673

Summary for 4PJT
Entry DOI10.2210/pdb4pjt/pdb
Related4PJV
DescriptorPoly [ADP-ribose] polymerase 1, SULFATE ION, (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one, ... (5 entities in total)
Functional Keywordsparp1, inhibitor, complex, transferase-transferase inhibitor complex, transferase/transferase inhibitor
Biological sourceHomo sapiens (Human)
Cellular locationNucleus : P09874
Total number of polymer chains4
Total formula weight168887.98
Authors
Aoyagi-Scharber, M.,Gardberg, A.S.,Arakaki, T.L. (deposition date: 2014-05-12, release date: 2014-09-24, Last modification date: 2024-10-16)
Primary citationAoyagi-Scharber, M.,Gardberg, A.S.,Yip, B.K.,Wang, B.,Shen, Y.,Fitzpatrick, P.A.
Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone.
Acta Crystallogr.,Sect.F, 70:1143-1149, 2014
Cited by
PubMed Abstract: Poly(ADP-ribose) polymerases 1 and 2 (PARP1 and PARP2), which are involved in DNA damage response, are targets of anticancer therapeutics. BMN 673 is a novel PARP1/2 inhibitor with substantially increased PARP-mediated tumor cytotoxicity and is now in later-stage clinical development for BRCA-deficient breast cancers. In co-crystal structures, BMN 673 is anchored to the nicotinamide-binding pocket via an extensive network of hydrogen-bonding and π-stacking interactions, including those mediated by active-site water molecules. The novel di-branched scaffold of BMN 673 extends the binding interactions towards the outer edges of the pocket, which exhibit the least sequence homology among PARP enzymes. The crystallographic structural analyses reported here therefore not only provide critical insights into the molecular basis for the exceptionally high potency of the clinical development candidate BMN 673, but also new opportunities for increasing inhibitor selectivity.
PubMed: 25195882
DOI: 10.1107/S2053230X14015088
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.35 Å)
Structure validation

229380

PDB entries from 2024-12-25

PDB statisticsPDBj update infoContact PDBjnumon